Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPN10200 dose-escalation and dose-finding study for upper facial lines
2024-512782-14-00Phase 2Authorised
- Sponsor
- Ipsen
- Start
- Mar 2024
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of corabotase in upper facial lines (3 arms), sponsored by Ipsen. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and 7 more. Planned start Mar 2024; status: authorised.
02
Drugs
corabotase
03
Conditions
upper facial lines
Beyond the preview
Go deeper on 2024-512782-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512782-14-00.